(Q37945385)

25 August 2017

title

Fifty years in the vineyard of transplantation: looking back (English)

1 reference

25 August 2017

B D Kahan

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Transplantation Proceedings

25 August 2017

published in

1 reference

25 August 2017

volume

43

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

2853-2859

1 reference

The use of antigenic tissue extracts to weaken the immunological reaction against skin homografts in mice

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

7 January 2021

Transplantation Antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

ISOLATION OF A SOLUBLE TRANSPLANTATION ANTIGEN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Electrophoretic purification of a water-soluble guinea pig transplantation antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Water-soluble human transplantation antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Solubilization and partial purification of mouse histocompatibility antigens from a membranous lipoprotein fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Salt Extraction of Soluble HL-A Antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Quantitative Studies on Tissue Transplantation Immunity. III. Actively Acquired Tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Induction of immunity and tolerance in vitro by hapten protein conjugates. I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

A potential synergistic effect of donor antigenic extracts and cyclosporine on the prolongation of rat renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Prolongation of rat kidney allografts by pretransplant administration of donor antigen extract or whole blood transfusion combined with a short course of cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Prolongation of allograft survival by repeated cycles of donor antigen and cyclosporine in rat kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Soluble antigen and cyclosporine-induced specific unresponsiveness in rats. Frequency of alloantigen-specific T cytotoxic cells in normal, sensitized, and unresponsive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Nature of the suppressor cells mediating prolonged graft survival after administration of extracted histocompatibility antigen and cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

The immunosuppressive action of suppressor cells from antigen-cyclosporine-treated hosts on renal allograft survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Specificity and biological activity of extracted murine tumor-specific transplantation antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Localization of cryptic tolerogenic epitopes in the alpha1-helical region of the RT1.Au alloantigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Allochimeric class I MHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Allochimeric therapy induces unique regulatory T cells that mitigate chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Cosmas and Damian in the 20th Century?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

The synergistic effect of total-lymphoid irradiation with extracted donor alloantigen in inducing transplantation unresponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Immunosuppressive effects of defibrotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Methoxyethyl modification of phosphorothioate ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

7 January 2021

Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

7 January 2021

The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

7 January 2021

The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.08.058

7 January 2021

10.1016/J.TRANSPROCEED.2011.08.058

Identifiers

DOI

1 reference

25 August 2017

1 reference